Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices
Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, announced the completion of its previously announced acquisition of Hint, Inc., a privately held company doing business under the name HintMD. Revance issued a total of 8,572,213 shares of common......
